Clinical Scorecard: A Two-Biomarker Signal for Alzheimer’s Disease
At a Glance
| Category | Detail |
|---|---|
| Condition | Alzheimer’s Disease |
| Key Mechanisms | Combination of plasma biomarkers p-tau217 and eMTBR-tau243 to identify tau pathology and cognitive impairment. |
| Target Population | Patients with cognitive symptoms including subjective cognitive decline, mild cognitive impairment, or dementia. |
| Care Setting | Secondary memory clinics and research settings. |
Key Highlights
- Combination of p-tau217 and eMTBR-tau243 improves identification of established Alzheimer’s disease.
- 81% accuracy and 84% positive predictive value for established disease with combined biomarkers.
- eMTBR-tau243 levels correlate with tau accumulation and cognitive decline.
- Two-step testing strategy enhances diagnostic precision.
- Study population included 572 patients with cognitive symptoms.
Guideline-Based Recommendations
Diagnosis
- Use plasma p-tau217 to detect amyloid pathology.
- Follow with eMTBR-tau243 to assess tau pathology.
Management
- Consider therapies targeting amyloid or tau based on biomarker levels.
Monitoring & Follow-up
- Monitor cognitive performance and tau PET signal over time.
Risks
- Potential for misclassification of asymptomatic amyloid pathology.
Patient & Prescribing Data
Patients with cognitive symptoms and positive plasma p-tau217 results.
Higher eMTBR-tau243 levels indicate greater tau burden and faster cognitive decline.
Clinical Best Practices
- Implement a two-step biomarker testing strategy in clinical assessments.
- Stratify patients based on biomarker results for tailored management.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
